# InnoPharmax

Source: https://onco.cc/companies/innopharmax/  
OnCo record `innopharmax` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

InnoPharmax is a Taiwanese pharmaceutical company running phase 3 trials of D07001, its oral formulation of the chemotherapy irinotecan, in biliary tract cancer.

## Summary

InnoPharmax, based in Taipei, develops oral formulations of established cancer drugs. Its lead programme D07001 is an oral form of irinotecan designed to allow outpatient dosing, in phase 3 trials for advanced biliary tract cancer after first-line chemotherapy. Sponsor and trial facts are from the ClinicalTrials.gov registry.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: InnoPharmax Inc.
- Tags: ctgov-sponsor
- HQ: Taipei
- Type: biotech

## Sources

- ClinicalTrials.gov: trials led by InnoPharmax: https://clinicaltrials.gov/search?lead=InnoPharmax

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/)
- drugs: [D07001](https://onco.cc/drugs/d07001/)
- trials: [D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06622057/), [Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer](https://onco.cc/trials/nct05065957/)

---
JSON: https://onco.cc/api/v1/entities/innopharmax.json